Risco de câncer em idosas BRCA-mutado e sobrevida em 5 anos do estudo WSG-ADAPT-TP

Notas do episódio

Referências: Metcalfe, KA, Gronwald, J, Tung, NM, et al. The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023; 129( 6): 901- 907. doi:10.1002/cncr.34615ou https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34615 Harbeck N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Kreipe HH, Gluz O et al. WSG-ADAPT investigators. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023 Feb 21:JCO2201816. doi: 10.1200/JCO.22.01816. Epub ahead of print. PMID: 36809046. https://ascopubs.org/doi/abs/10.1200/JCO.22.01816